All In Biotech

Drug Trial Radar · NCT07721610

Omega-3-Based Nutraceutical Supplementation as Adjunctive Therapy in Adults With Otitis Media With Effusion: A Multicenter, Double-Blind, Randomized Placebo-Controlled Trial

Last checked: Nov 19, 2026Latest source record: Jul 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 501 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

501

Actual

Start

Oct 1, 2025

Primary completion

Apr 1, 2026

Study completion May 1, 2026

Sponsor

Lead sponsor
Isola Tiberina - Gemelli Isola Hospital, Rome, ItalyAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 23, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Brief Summary - OMENUTS Trial Otitis media with effusion (OME) is a condition in which fluid accumulates in the middle ear, causing conductive hearing loss, ear fullness, tinnitus, and Eustachian tube dysfunction. Although OME is well-recognized in children, it also affects adults, in whom it is frequently under-diagnosed and inadequately treated. No established, well-tolerated pharmacological therapy currently exists for adult OME, and current medical management options - including antihistamines, corticosteroids, and mucolytics - have shown inconsistent efficacy in clinical trials. Omega-3 polyunsaturated fatty acids and associated nutraceutical compounds have well-documented anti-inflammatory and immunomodulatory properties that are mechanistically relevant to the pathophysiology of OME, which is driven by chronic low-grade mucosal inflammation, Eustachian tube dysfunction, and impaired mucociliary clearance. A nutraceutical combination containing omega-3 fatty acids, Spirulina, magnesium, and vitamin B6 has previously demonstrated efficacy in reducing inflammatory biomarkers and improving clinical outcomes in allergic rhinitis - a condition sharing key pathophysiological features with OME. The OMENUTS trial is a multicenter, double-blind, randomized placebo-controlled trial designed to evaluate the efficacy of this nutraceutical combination as adjunctive therapy in adults with confirmed OME. The trial is conducted across three tertiary referral centres in Italy: Isola Tiberina - Gemelli Isola Hospital (Rome), the University of Catanzaro (Catanzaro), and Tortorella Clinic (Salerno). A total of 501 adult participants aged 18 to 70 years with a confirmed diagnosis of OME - established by otoscopic examination and tympanometry (type B curve) of at least 4 weeks' duration - are randomized in a 1:1:1 ratio to one of three groups. All participants receive a shared background therapy of intranasal mometasone furoate spray and oral deflazacort for three weeks. In addition to the background therapy, participants in Group 1 (intervention group) receive the nutraceutical combination (omega-3 fatty acids, Spirulina, magnesium, and vitamin B6; one tablet daily) for three weeks; participants in Group 2 (active control group) receive oral bilastine 20 mg daily for three weeks; and participants in Group 3 (placebo group) receive an identical placebo tablet daily for three weeks. The co-primary outcomes are tympanometric resolution - defined as normalization of the tympanometric curve from type B to type A - and audiometric improvement - defined as a reduction in pure-tone average of more than 15 dB HL - both assessed at the end of treatment (week 3, T1). Secondary outcomes include changes in patient-reported symptom severity (VAS), Eustachian tube dysfunction symptoms (ETDQ-7), psychosocial impact of hearing impairment (HHIA), and Eustachian tube patency assessed by the Valsalva maneuver. A 60-day post-treatment follow-up visit (T2) is included to evaluate recurrence rates across groups. Randomization is computer-generated via REDCap, stratified by site, and implemented with permuted blocks of variable size. The trial is conducted under a double-blind design, with all investigational products identical in appearance, odour, and taste. Safety outcomes, including the incidence and nature of adverse events classified according to MedDRA criteria, are monitored continuously throughout the study. The primary analysis is conducted on a modified intention-to-treat basis, including all participants who received at least one dose of the assigned treatment and completed at least one post-baseline assessment. The trial is conducted in accordance with the Declaration of Helsinki, CONSORT guidelines, and was approved by the Institutional Review Board of the Region of Calabria, Italy (approval code: 177/2026).

Conditions

  • Otits Media With Effusion

Interventions

  • Omega-3-based nutraceutical combination (Otoair Flogo)Dietary supplement

    Nutraceutical combination containing omega-3 fatty acids, Spirulina algae, magnesium, and vitamin B6 (Otoair Flogo, Shedirpharma s.r.l., Piano di Sorrento, Naples, Italy). One tablet administered orally at bedtime for 3 weeks. Assigned to Group 1 (intervention group) in addition to shared background therapy.

  • Bilastine 20 mgDrug

    Oral bilastine 20 mg administered once daily at bedtime for 3 weeks. Assigned to Group 2 (active control group) in addition to shared background therapy.

  • Placebo Tablet or CapsuleDrug

    Oral placebo tablet (maltodextrins and stabilizers) administered once daily at bedtime for 3 weeks, identical to the active treatment in appearance, odour, and packaging. Assigned to Group 3 (placebo group) in addition to shared background therapy.

  • Intranasal mometasone furoate sprayDrug

    Intranasal mometasone furoate spray administered as one puff per nostril twice daily for 3 weeks as shared background therapy. Administered to all three groups regardless of randomization allocation.

  • Oral deflazacort 30 mgDrug

    Oral deflazacort 30 mg administered once daily in the morning for 6 days as shared background therapy. Administered to all three groups regardless of randomization allocation.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Tympanometric resolutionTime frame: Week 3 (end of treatment, T1)
  2. Audiometric improvementTime frame: Week 3 (end of treatment, T1)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Isola Tiberina - Gemelli Isola Hospital Rome, Italy

    Roma, Italy, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.